These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21615547)

  • 1. The BH3-mimetic ABT-737 inhibits allogeneic immune responses.
    Cippà PE; Kraus AK; Edenhofer I; Segerer S; Chen J; Hausmann M; Liu Y; Guimezanes A; Bardwell PD; Wüthrich RP; Fehr T
    Transpl Int; 2011 Jul; 24(7):722-32. PubMed ID: 21615547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics.
    Karlberg M; Ekoff M; Huang DC; Mustonen P; Harvima IT; Nilsson G
    J Immunol; 2010 Aug; 185(4):2555-62. PubMed ID: 20639495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Bcl-2 inhibition by ABT-737 and cyclosporine A.
    Cippà PE; Kamarashev J; Chen J; Kraus AK; Segerer S; Feldmeyer L; Fehr T
    Apoptosis; 2013 Mar; 18(3):315-23. PubMed ID: 23208368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Bcl-2 family antagonist ABT-737 in collagen-induced arthritis.
    Lawlor KE; Smith SD; van Nieuwenhuijze A; Huang DC; Wicks IP
    J Leukoc Biol; 2011 Oct; 90(4):819-29. PubMed ID: 21719460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.
    Tagscherer KE; Fassl A; Campos B; Farhadi M; Kraemer A; Böck BC; Macher-Goeppinger S; Radlwimmer B; Wiestler OD; Herold-Mende C; Roth W
    Oncogene; 2008 Nov; 27(52):6646-56. PubMed ID: 18663354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.
    Karlsson H; Lindqvist AC; Fransson M; Paul-Wetterberg G; Nilsson B; Essand M; Nilsson K; Frisk P; Jernberg-Wiklund H; Loskog A
    Cancer Gene Ther; 2013 Jul; 20(7):386-93. PubMed ID: 23788110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs.
    Carrington EM; Vikstrom IB; Light A; Sutherland RM; Londrigan SL; Mason KD; Huang DC; Lew AM; Tarlinton DM
    Proc Natl Acad Sci U S A; 2010 Jun; 107(24):10967-71. PubMed ID: 20534453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
    Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
    Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
    Mason KD; Khaw SL; Rayeroux KC; Chew E; Lee EF; Fairlie WD; Grigg AP; Seymour JF; Szer J; Huang DC; Roberts AW
    Leukemia; 2009 Nov; 23(11):2034-41. PubMed ID: 19641525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
    Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T
    Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting multiple arms of the apoptotic regulatory machinery.
    Dai Y; Grant S
    Cancer Res; 2007 Apr; 67(7):2908-11. PubMed ID: 17409392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress.
    Howard AN; Bridges KA; Meyn RE; Chandra J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):41-54. PubMed ID: 19404643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
    Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
    Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
    High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
    Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL.
    Ezzoukhry Z; Louandre C; François C; Saidak Z; Godin C; Mazière JC; Galmiche A
    Mol Pharmacol; 2011 Jun; 79(6):997-1004. PubMed ID: 21393385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737.
    Wiegmans AP; Alsop AE; Bots M; Cluse LA; Williams SP; Banks KM; Ralli R; Scott CL; Frenzel A; Villunger A; Johnstone RW
    Cancer Res; 2011 May; 71(10):3603-15. PubMed ID: 21398407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1.
    Zheng L; Yang W; Zhang C; Ding WJ; Zhu H; Lin NM; Wu HH; He QJ; Yang B
    Cancer Lett; 2011 Oct; 309(1):27-36. PubMed ID: 21664043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
    Chauhan D; Velankar M; Brahmandam M; Hideshima T; Podar K; Richardson P; Schlossman R; Ghobrial I; Raje N; Munshi N; Anderson KC
    Oncogene; 2007 Apr; 26(16):2374-80. PubMed ID: 17016430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
    Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.